Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Sleep Apnoea
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Sleep Apnoea
    Weight Loss Alleviates Sleep Apnoea in Obese Men - (DGNews)
    Sleep Apnoea May Cause Heart Disease In Kidney Transplant Patients - (DGNews)
    TopAbstracts in Sleep Apnoea 11/16/2009 - (DGNews)
    Valsartan Better Than Continuous Positive Airway Pressure Therapy in Previously Untreated Hypertensive Sleep Apnoea: Presented at CHEST 2009 - (DGDispatch)
    TopAbstracts in Sleep Apnoea 10/19/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Sleep Apnoea
    • Managing Insomnia in Older Women: A Case-Based Approach
    • Evaluation and Management of a 53-Year-Old Woman Presenting With Disturbed Sleep
    • Insomnia Treatment Considerations in a 65-Year-Old Woman With Urinary Urgency
    • Sleep Apnea and the Importance of Patient Screening
      Complex Sleep Apnea

      Webcasts/CME archive

       Recent cases - Sleep Apnoea
        Probable Causal Link Between Epilepsy and Sleep Apnea: Case Report
        Ultrasound Guided Femoral Nerve Block in an Obese Patient with a Patellar Tendon Tear and Severe Obstructive Sleep Apnea
        Continuous Positive Airway Pressure Ameliorated Severe Pulmonary Hypertension Associated with Obstructive Sleep Apnea
        Small B Cell Lymphocytic Lymphoma Presenting as Obstructive Sleep Apnea
        Acquired Ondine's Curse

        Cases archive
          




        my personal edition > sleep apnoea > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Modafinil Improves Quality Of Life In Obstructive Sleep Apnea Patients: Presented at CHEST

        By Peggy Peck
        Special to DG News

        SAN DIEGO, CA -- November 6, 2002 -- Results of a 12-week randomized trial suggest that modafinil significantly improves wakefulness and quality of life (QOL) and is well tolerated when used as an adjunct to nasal continuous positive airway pressure (nCPAP) therapy in patients with obstructive sleep apnea and residual excessive sleepiness.

        Jonathan R.L. Schwartz, MD, of Integris Sleep Disorders Centers of Oklahoma, Oklahoma City, United States, presented the findings at CHEST 2002, the annual meeting of the American College of Chest Physicians.

        The researchers recruited 323 patients who were randomized to placebo (n=108), modafinil 200 mg (109) or 400 mg once daily (n=106).
        Modafinil doses were titrated from 100 mg/d to 200 mg/d or 400 mg/d within one week. Efficacy outcomes included changes from baseline in objectively measured alertness (Maintenance of Wakefulness Test [MWT]) and subjective sleepiness (Epworth Sleepiness Scale [ESS]) at weeks 4, 8, and 12. Quality of life was evaluated using the Functional Outcomes of Sleep Questionnaire (FOSQ) and nCPAP use and adverse events (AEs) were monitored.

        Modafinil significantly improved patients' ability to sustain wakefulness on the MWT compared with placebo (all p<0.001; figure). Modafinil significantly improved wakefulness as measured by ESS scores at all time points (4.5 point decrease at week 12 for both doses) compared with placebo (1.9 point decrease; p<0.0001).

        Modafinil was associated with significant improvement in QOL, with greater changes from baseline at week 12 in total FOSQ score (p<0.001) and domain scores for vigilance (p=0.0005), general productivity (p<0.0008), activity level (p<0.03), and intimacy (p<0.03) compared with placebo. Modafinil had no significant effect on nCPAP use.

        The most common AEs in the modafinil and placebo groups were headache (26 and 12 percent), nausea (11 and 2 percent), and anxiety (8 and 2 percent).

        The study was supported by a grant from Cephalon, Inc., West Chester, Pennsylvania, United States.



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send